### RESEARCH



**Open Access** 

# The vitamin D receptor and inducible nitric oxide synthase associated pathways in acquired resistance to *Cooperia oncophora* infection in cattle

Robert W Li<sup>\*</sup>, Congjun Li, Louis C Gasbarre

#### Abstract

*Cooperia oncophora* is an economically important gastrointestinal nematode in ruminants. Acquired resistance to *Cooperia oncophora* infection in cattle develops rapidly as a result of prior infections. Naïve cattle, when given a primary infection of high-dose infective L3 larvae, develop a strong immunity to subsequent reinfection. Compared to primary infection, reinfection resulted in a marked reduction in worm establishment. In order to understand molecular mechanisms underlying the development of acquired resistance, we characterized the transcriptomic responses of the bovine small intestine to a primary infection and reinfection. A total of 23 pathways were significantly impacted during infection. The vitamin D receptor activation was strongly induced only during reinfection, suggesting that this pathway may play an important role in the development of acquired resistance via its potential roles in immune regulation and intestinal mucosal integrity maintenance. The expression of inducible nitric oxide synthase (NOS2) was strongly induced during reinfection but not during primary infection. As a result, several canonical pathways associated with NOS2 were impacted. The genes involved in eicosanoid synthesis, including prostaglandin synthase 2 (PTGS2 or COX2), remained largely unchanged during infection. The rapid development of acquired resistance may help explain the lack of relative pathogenicity by *Cooperia oncophora* infection in cattle. Our findings facilitate the understanding of molecular mechanisms underlying the development of acquired resistance, which could have an important implication in vaccine design.

#### Introduction

*Cooperia oncophora* is one of the most economically important gastrointestinal nematodes in ruminants that result in production inefficiency. In Brazil, over 70% of parasites recovered from cattle grazed on pasture belong to the genus *Cooperia* [1]. While clinical symptoms are generally absent or relatively mild, *C. oncophora* infection has been shown to reduce live weight gain as much as 13.5% of total cattle bodyweights [2], possibly due to inappetence and nutritional deficiency. Pathophysiological changes induced by infection are typically restricted to the site of infection, mainly in the duodenum and jejunum. These changes include morphological and structural alterations in intestinal villi [2,3], loss of plasma protein into the gut [3] and enhanced mucus excretion [3,4].

\* Correspondence: robert.li@ars.usda.gov

Animal and Natural Resources Institute, United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA

C. oncophora infection in cattle elicits a Th2-like immune response, characterized by up-regulation of IL-4 and the involvement of both eosinophils and mucosal IgA [4-7]. Host serological response to C. oncophora infection has been extensively studied [6,8-10]. C. oncophora-specific serum and mucosal IgG1 and IgA are strongly induced upon experimental challenge in cattle [8]. Moreover, the levels of Cooperia-specific IgA are significantly higher in intermediate responders than in low responders in cattle [9] and expulsion of the adult *Cooperia* worm appeared to be associated with a significant increase in mucosal IgA and an influx of eosinophils [6]. PIGR, a gene responsible for trans-epithelial transport of polymeric immunoglobulins, such as IgA dimers and IgM pentamers, into mucosal and glandular secretions, is strongly up-regulated in the heifers resistant to parasitic nematodes after experimental parasite challenge [7]. The peak in antibody titres is preceded by a significant increase in B and MHCII<sup>+</sup> cells in the draining lymph nodes, suggesting that B cells may play an



© 2011 Li et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

important role in development of acquired immunity against the parasite [8].

In ruminants, adult animals often exhibit acquired resistance to gastrointestinal nematodes. This process tends to display a temporal characteristic. The ability to reject incoming larvae is first acquired, followed by depressing female fecundity and then by expelling adult worms by the host. The prevention of worm establishment in the host tissue, which is determined by host age, seems most important and requires a threshold worm burden in order to invoke a strong immune response [11]. Compared to the abomasal nematode Ostertagia ostertagi, which requires a prolonged exposure before acquired resistance becomes effective [12,13], protective immunity to reinfection in cattle develops rapidly following a primary C. oncophora infection. A significant reduction in worm burdens can be achieved in primed cattle with a primary infection [14]. In these animals, acquired resistance is also manifested by increased percentage of L4 larvae. In addition, worm length and fecundity are also significantly reduced. This observed immunity is also confirmed in cattle during natural infection. Calves moderately exposed to *C. oncophora* during the first grazing season are absent of any C. oncophora larvae in their fecal cultures during the second grazing season [15,16]. Accumulated evidence suggests that a rapid development of protective immunity may well explain relatively mild clinical symptoms and lack of severe pathogenicity observed in cattle exposed to *C. oncophora* infections. While the effect of host response types or genetic factors on worm establishment and infection doses on worm morphology and reproduction are well understood, molecular mechanisms underlying the development of acquired resistance in cattle have not received any attention. In this study, we aim to understand the underlying mechanisms that contribute to the development of acquired resistance against C. oncophora infection in cattle, which should have a positive impact on formulating optimal drug-independent nematode control strategies.

#### Materials and methods

#### Animals and worm burdens

Sixteen Holstein bull calves were purchased locally within 48 h after birth. The animals were fed *ad libitum* with a standard calf ration and maintained on concrete for the duration of the experiment. These animals were randomly divided into 4 groups (naïve control, primary infection, drug-treated control, reinfection) with 4 animals in each group. After reaching ~ 4 months of age, twelve of these 16 nematode-naïve animals were orally infected with a single dose of *C. oncophora* infective L3 larvae ( $10^5$  larvae per animal) for 14 days post infection (dpi). The L3 larvae were obtained from cultures maintained at the USDA-ARS Beltsville facilities. Four uninfected naïve animals

were used as controls. Four out of the 12 infected animals (primary infection) at 14 dpi and four naïve control animals were sacrificed. The remaining 8 infected calves were treated with a 2× labeled dose of fenbendazole (Safe-Guard) to remove existing parasites. These calves were allowed to rest for 30 days on concrete. Four of the 8 drug-treated calves were then infected with a single dose of 10<sup>5</sup> L3 larvae per animal for 14 days (reinfection) and the remaining four drug-treated calves remained uninfected and served as drug-treated controls. Small intestine tissues were collected from the jejunum approximately three meters from the pyloric sphincter and snap frozen in liquid nitrogen prior to storage at - 80°C until total RNA was extracted. The animal maintenance and handling were based on the protocol approved by The USDA-ARS Animal Care and Use Committee; and Institutional Animal Care and Use Committees guidelines were strictly followed. Fecal egg count (egg per gram of feces or EPG) was monitored during the repeat infection experiment using zinc sulfate double centrifugation and parasite burdens were determined as previously described [13].

#### RNA Extraction, real-time RT-PCR, and microarray analysis

Total RNA extraction, real-time RT-PCR and microarray fabrication and hybridization were performed as previously described [7,17]. Briefly, total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) and further purified using an RNeasy Mini kit (Qiagen, Valenica, CA, USA). RNA integrity was verified using a Bioanalyzer 2100 (Agilent, Palo Alto, CA, USA). For real-time RT-PCR, the cDNA synthesis was performed with an iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA). Realtime RT-PCR analysis was carried out with the iQ SYBR Green Supermix kit (Biorad) using 200 nM of each amplification primer and the 1<sup>st</sup>-strand cDNA (100 ng of the input total RNA equivalents) in a 25 µL reaction volume as described [7]. The amplification was carried out on an iCycler iQ<sup>™</sup> Real Time PCR Detection System (BioRad) with the following profile: 95°C-60 s; 40 cycles of 94°C-15 s, 60°C-30 s, and 72°C-30 s. A melting curve analysis was performed for each primer pair. The ribosomal protein S29 (RPS29), with relatively constant expression levels across all experiment samples, was used as an endogenous control. Relative gene expression data was calculated using the  $2^{-\Delta\Delta CT}$  method [18]. The fold change was normalized against the naive group.

The bovine microarray, which included 86 191 unique 60mer oligonucleotides synthesized in situ, each repeated 4 times on the microarray, representing 45 383 bovine genes and/or expressed sequence tags (ESTs), was previously described [17]. After hybridization, scanning and image acquisition, data were extracted from raw images using NimbleScan software (Roche, Indianapolis, IN, USA). A total of 16 microarrays, 4 biological replicates

per treatment group, were used in this experiment (GEO accession# GSE24402). Relative signal intensities (log2) for each feature were generated using the robust multiarray average algorithm [19]. The data were then processed based on the quantile normalization method [20]. The background-adjusted, normalized, and logtransformed intensity values were further analyzed using MeV v4.2. [21]. Significantly regulated genes were identified using the method suggested by Guo et al. [22] based on their significance (P < 0.05) and followed by fold change (2 fold as a cutoff). A nucleotide BLAST was conducted against the Reference mRNA Sequences Database (RefSeq) for all sequences that were significantly impacted during infection using 60mer oligo sequences on the microarray (cutoff E Value  $< 10^{-8}$ ). These genes are listed in Additional file 1. After removing redundancy in which a gene was represented by multiple sequences, genes with annotation and approved gene symbols (Table 1) were used for pathway analysis discussed below.

Genes significantly regulated during infection were analyzed using Ingenuity Pathways Analysis (IPA) software v8.7 (Ingenuity Systems, Redwood City, CA, USA) as described previously [13,23]. Genes significantly upregulated and down-regulated were analyzed separately. Genes with known gene identifiers (gene symbols) and their corresponding expression values were uploaded into the software. Canonical pathways were identified based on two parameters: (1) A ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway, and (2) a P value calculated using Fischer's exact test, which determines the probability that the association between the genes in the data set and the canonical pathway is due to chance alone.

#### Western blot analysis

Western blot analysis was essentially the same as described [13]. Briefly, crude proteins were extracted from bovine small intestine samples using Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, USA) with a protease inhibitor cocktail (Sigma, St. Louis, MO, USA) added prior to use. After homogenization, the samples were briefly centrifuged at 4°C for 2 min at  $10\ 000 \times g$  to remove debris. Crude protein was quantified using a modified Branford method and Western blot analysis performed as described [4]. Briefly, the protein from different samples was separated by SDS PAGE on 2 identical 4 to 20% polyacrylamide gradient gels. One gel was stained with Simply Blue Safestain (Invitrogen) and served as loading control. Another gel was used for Western blot and imaging analysis. The Western blot was probed with the following primary antibodies, SPP1 (OPN) mouse monoclonal antibody (sc-21742, Santa Cruz Biotechnology, Santa Cruz, CA,

USA) and GCNT3 goat polyclonal antibody (ab77728, Abcam, Cambridge, MA, USA). After washing, these blots were incubated with an IRdye labeled secondary antibody (Li-Cor Bioscience, Lincoln, NE, USA). The bands were detected using a Li-Cor Odyssey Infrared Imaging System (Li-Cor). The relative density of the target bands on the blots was quantified using the imaging software UN-SCAN-IT (Silk Scientific, Orem, UT, USA).

#### Results

#### Parasitology and worm counts

The naïve control calves remained worm-free during the experiment. No worms were recovered from drug-treated control animals, suggesting that a 2× labeled dose of fenbendazole (Safe-Guard) is sufficient to eliminate existing parasites. EPG was monitored weekly during the rest period. A low EPG value (EPG = 8) was detected only in one of the animals in a single time point, providing further evidence the efficacy of drug drenching. Approximately a 56% reduction in worm burden was observed in reinfected calves (mean worm counts  $\pm$  SD = 10 334  $\pm$  3 585) compared to the animals with only a primary infection  $(23\ 883\ \pm\ 7\ 833)$  at 14 dpi). The difference is marginally significant (P < 0.1), probably due to a substantial variation in worm burden in an out-bred population used in this challenge experiment. While uncharacterized genetic makeup of experiment animals and a small sample size used in challenge studies are a major concern, a significant reduction in worm burden and a higher percentage of immature larvae recovered in reinfected animals (15.2% vs. 9.4% in primarily infected animals, P < 0.1) suggested these animals had indeed acquired protective immunity to infection.

#### Transcriptomic profiles and pathway analysis

Transcriptomic disruptions in the bovine jejunum induced by *C. oncophora* between a primary infection and a drug-attenuated reinfection were compared using a bovine high-density microarray consisting of 86 191 unique 60mer oligonucleotides. Based on both significance derived from an unpaired *t*-test ( $P \le 0.05$ ) and fold change, a total of 308 unique sequences were impacted during infection. The alteration in the bovine transcriptome by the parasite infection appeared to be minimal; and only a small fraction of the transcriptome (< 1%) was affected. Among the 308 sequences induced, eighty unique genes that were significantly up-regulated can be identified with annotation (Table 1).

Approximately forty genes were significantly up-regulated during the primary infection only (Table 1). These genes include basic leucine zipper and W2 domains 1 and 2 (BZW1 and BZW2), dendrin (DDN), glucosaminyl (N-acetyl) transferase 3, mucin type (GCNT3), hepatocyte growth factor (HGF), major histocompatibility

| ARC01     similar to ATP-binding casette sub-family G member 1     2.29*     1.08       NNL_157012     ALOX15     arachidonate 1-5/igoxygenase     1.27     2.42*       NNL_051083081     BAALC     brain and acute leakenia, cytoplasmic     0.51     2.07*       NNL_0510761033     BST41     similar to bettrophin 4     0.74     2.05*       NNL_0010761951     CABL     cable clucic zigore and V2 domains 2     3.88*     0.66       NNL_0010761951     CABL     cable clucic zigore and V2 domains 2     3.88*     0.66       NNL_0010707942     CCT3     cable clucic zigore and V2 domains 2     3.88*     0.66       NNL_0010707942     CCR3     cable clucic zigore and V2 domains 2     3.88*     0.62       NNL_0010707943     CCR3     cable clucic zigore and V2 domains 2     3.88*     1.15     2.09*       NNL_00107070431     CDR4     similar to cable in MCC3192 protein     2.05     1.08     3.02**       NNL_00101005051     DIN1     dendrin     2.09*     0.81     3.02**       NNL_00101005051     DIN1     dendrin     2.09*     0.24*   | Bovine RefSeq_ID | Symbol   | Description   | Primary infection | Reinfection |
|--|------------------|----------|---|-------------------|-------------|
| NML 199012     ALX15     arachidonate 15 Ipoorgenase     12.7     2.42*       NML 00108306A1     BAALC     brain and acute leukenia, cytoplasmic     0.74     2.07*       NML 00108306A1     BCS14     brain and acute leukenia, cytoplasmic     0.74     2.07*       NML 0010761551     CALB1     calbindin 1, 28 kDa     3.89*     0.66       NML 0010761551     CALB1     calbindin 1, 28 kDa     1.5     2.13*       NML 0010761551     CALB1     calbindin 1, 28 kDa     1.5     2.08**       NML 00101793412     CCT3     chaperonin containing TCP1, subunit 3 (gamma)     2.06*     0.81**       NML 00101793412     CCB4     calbindin 1, 28 kDa     1.15     2.09*       NML 001013414     CRP8     similar to calcinci and hepatic tumor over-expressed protein     2.04*     0.87*       NML 001013401     CM6     adminin to basin giogenic induce, 61     0.87     2.24**       NML 00101301.1     DMN     dendrin respectate rich, signalitic tumor over-expressed protein     2.04*     2.04**       NML 001013031.1     DMN     dendrin respectate richar (Aspaca spressed protein)     0.87  | VAA 507020.4     | 10001    |   | 2.20*             | 1.00        |
| NuL_0108588.1     BALC     brain and acute leakernia, optoplasmic     0.14     2.05*       XM_S87613.3     BEST4     similar to basinophin 4     0.74     2.05*       XM_S87613.3     BEXT     basic leucicia paper and W2 domains 1     2.78*     1.33       NM_00104961.1     BZW2     basic leucicia paper and W2 domains 2     3.9*     0.66       NM_001071974.2     CCT3     chaperonin containing TCP1, subunit 3 (gamma)     2.06*     0.57       XM_S93072.4     CDR4     similar to acaherin-like 26     0.57     1.56       NM_001017984.2     CDR4     similar to acaherin-like 26     0.57     1.56       NM_00101601.0     COL124     similar to acaherin-like 26     0.57     1.56       NM_00101801.0     COL174     coloper, type VM, ajota 1     0.76     2.62*       NM_001016031.0     CMR1.     coloper, type VM, ajota 1     0.76     2.62*       NM_001040321.0     DNN1.1     OMR1.     0.74     2.42*       NM_001040321.0     DNN1.1     OMR1.     2.77*     1.33       NM_001040321.0     DNN1.1     Mener, type JMain ton  | —                |          |   |                   |             |
| XM_8376913     BC34     similar to bestrophin 4     0.74     205*       XM_8761033     BZW1     basic lexcine apper and W2 domains 1     2.78*     1.33       XM_001106/0151     CALB     cabinedin 1, 28 kDa     1.15     2.13*       NM_001076/053     CALB     cabinedin 1, 28 kDa     1.15     2.13*       NM_0010761951     CALB     cabinedin 1, 28 kDa     1.05*     2.13*       NM_0010761951     CALB     cabinedin 1, 28 kDa     1.05*     2.04***       NM_0010107041     CBFB     similar to cabinerihite 26     3.94****     1.26*       NM_0010107041     CBFB     similar to cabine binding protein (CEBP, beta     1.15     2.09*       NM_0010107021     CN1741     colagenetic tumor over-expressed protein     2.0*     0.81*       NM_0010107023     DIX0     dendrine, indigenetic indicare, 61     0.87     2.37**     0.77*     1.73       NM_00101060231     DIX0     dendrine, indifferone, type     4.38*     2.11*     NM_001040031     DIX1     MIM+01*     2.20*     0.44*       NM_0010106051     DIX11     de   | _                |          |   |                   |             |
| XM_8/5130.3     BZW1     basic leucine zipper and W2 domains 1     2.28*     1.33       NM_00104961.1     BZW2     basic leucine zipper and W2 domains 2     3.84*     0.66       NM_001073942     CC13     chapeeonin containing TCP1, subunit 3 (gamma)     2.06*     0.52       XM_5837074     CDR3     similar to catherine/like 26     39.4****     13.08*       XM_000703242     CC13     similar to catherine intro over-expressed protein     2.05*     0.81       XM_0007032704     CDR4     catherine induce, 61     0.76*     0.81       XM_000101980.0     CL17A1     caldordynoine, npve XM1, alpha 1     0.76*     0.87*       NM_00104933.0     DIMT     DIMT     DIMT     DIMT     0.87*     0.87*       NM_00104933.0     DIMT     <   | _                |          |   |                   |             |
| NNL_001109961.1     BZW2     basic leucine zipper and W2 domains 2     38.9*     0.66       NNL_001017934.1     CAB     calationin 1, 28 KDa     1.15     2.13*       NNL_001017934.2     CCT3     diaperonin contraining TCPI, subunit 3 (gamma)     2.06*     0.52       NNL_983707.4     CDK8     similar to cohnerin-like 26     39.44***     1.06*       NNL_17678.1     CEBF     CCAAT/ernhancer binding protein (CEBP), beta     1.15     2.09*       NNL_001030401     CCH5     similar to colonic and hepatic tumor over-expressed protein     2.85*     0.87       NNL_00103043401     CCH6     cysteine-rich, angiogenic inducer, 61     0.87     2.85*     0.87       NNL_001040521     DIM1     divelinx, topolagenic inducer, 61     0.87     2.33*     0.97       NNL_001040521     DIM10     divelinx, topolagenic inducer, 61     0.87     1.11       NNL_001040521     DINOC11     dyneinx, copolagenic inducer, 61     0.87     2.33*     2.43*       NNL_001040521     DINOC111     dyneinx, copolagenic inducer, 61     0.87     1.11     2.43*     2.44*       NNL_0010405   | _                |          |   |                   |             |
| NM_0010703951     CALB1     calbindin 1, 28 kDa     1,15     2,13*       NM_0010703942     CCT3     chapteonin containing TCP1, subunit 3 (gamma)     2,66*     0,52       NM_0010703942     CCT3     chapteonin containing TCP1, subunit 3 (gamma)     2,66*     0,52       NM_001070391     CDR98     similar to caf681962 protein     2,55*     1,26       NM_001010390.1     CLR98     similar to caf681962 protein     2,00*     0,81       NM_001010390.1     CL761     colstain caf hepatic tumor over-expressed protein     2,00*     0,87     2,62**       NM_001014030.1     DMT1     DMM (anterlyladenosine transferase 1-like (S. cerevisiae)     2,37*     1,23       NM_00104603.1     DMT1     DMM (anterlyladenosine transferase 1-like (S. cerevisiae)     2,83*     2,41*       NM_00104603.1     DMT1     deiodinase, loadinyronine, type     0,44     2,49*       NM_00104603.1     DMT1     deiodinase, loadinyronine, type     0,41     2,99*       NM_00104603.1     FT1     capation protein 2 homolog (S. cerevisiae)     2,33     2,32*       NM_00104605.1     FT1     capation protein 2 homol   | —                |          |   |                   |             |
| NM_0010179342     CCT3     chaperonin containing TCP1, subunit 3 (gamma)     2.06*     0.52       NM_0802853     CDF20     similar to Caffern-like 26     3.964***     13.08*       NM_0537024     CDF20     similar to Caffern-like 26     3.25*     1.26       NM_0175784.1     CDF8     CCA/Torchancer binding protein (CEBP), beta     1.15     2.09*       NM_00101361.1     COL174.1     collagen, type XML alpha 1     0.76     2.62**       NM_00101361.1     CDF11     collagen, type XML alpha 1     0.76     2.62**       NM_001036340.1     CDF11     DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)     2.7**     1.23       NM_001040361.1     DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)     3.82**     1.11       NM_001040361.1     DIVC1     dendinaxe, indothyronine, type     3.83**     1.11       NM_001040361.1     EDP2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_001040565.1     F11     coaguidation factor XI     1.01     2.01**       NM_00105865.1     F11     coaguidation factor XI     1.01     2.01**  <   | —                |          |   |                   |             |
| XML_869285.3     CDH26     similar to AGC81962 portein     39.48***     13.08*       XML_887074     CDK8     similar to MCC81962 portein     2.55*     1.26       XML_001790249.1     CKAP5     similar to colonic and hepatic tumor over-expressed protein     2.20*     0.81       NML_00101300.1     COL17A1     colagen, type XML apidgenic inducer, 61     0.87     2.62**       NML_0010430.1     CVTAF     anglogenic inducer, 61     0.87     2.62**       NML_00104603.1     DIN1L     DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NML_00104605.21     DVNC1U1     deiodinase, loadthyronine, type     4.38*     2.41*       NML_00104665.21     DVNC1U1     deiodinase, loadthyronine, type     3.82**     1.11       NML_00104665.21     DVNC1U1     deiodinase, loadthyronine, type     3.82**     1.11       NML_00104665.21     DVNC1U1     deiodinase, loadthyronine, type     3.82**     1.11       NML_001075.91     ENCOD1     endonuclease domain containing 1     1.45     2.49*       NML_001075.91.1     ENCOD1     endonuclease domain containing 1     1.45   | —                |          |   |                   |             |
| XM_5837074     CDK8     similar to MGC81962 protein     255*     1.26       NM_1767881.     CEBPB     CCAAT/enhancer binding protein (C/EBP), beta     1.15     2.09*       NM_0017902201     CKAPS     similar to collonic and hepatic tumor over-expressed protein     2.20*     0.81       NM_00103440.1     CVR61     cystener-tch, anglogenic inducer, 61     0.87     2.62**       NM_00103430.1     DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NM_00104633.61     DIMTIL     dendrin ontorin 2 homolog (S. cerevisiae)     3.82**     1.11       NM_00104633.1     DIV     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_0010463.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_0010351.1     ELP2     elongation factor XI     1.01     2.01*       NM_01010381.4.1     ELP2     elongation factor XI     1.01     2.01*       NM_01010381.4.1     GRBRA2     garma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34*       NM_01010381.4.1     GCLM     glutamate-cystelm ligas     mucin type <td>—</td> <td></td> <td></td> <td></td> <td></td>   | —                |          |   |                   |             |
| NM_176788.1     CEBPB     CCAAT/enhancer binding protein (C/EBP), beta     1.15     2.09*       NM_001790249.1     CKAP5     similar to colonic and hepatic tumor over-expressed protein     2.20*     0.81       NM_0010301.1     COL TAT     colagen, type XVII, alpha 1     0.87     2.62**       NM_0010301.1     DDN     dendrin     0.87     2.62**       NM_00104052.1     DINT     dimethyladenosine transferase 1-like (S. cerevisiae)     2.7*     1.23       NM_00104052.1     DINT (LIII     deiodraze, iodothyronine, type     4.38*     2.41*       NM_00104052.1     DINTCILII     deiodraze, iodothyronine, type     3.82*     1.11       NM_00104052.1     DINTCILII     deiodraze, iodothyronine, type     3.82*     1.11       NM_00101485.4     EIN5     similar to ets variant gene 5 (ets-related molecule)     2.53     2.32*       NM_01010551.1     ENDOD1     endonuclease domain containing 1     1.45     2.49*       NM_010107584.1     GABRA5     garma-aminobutyric acid (GABA) receptor, alpha 2     1.57     2.34*       NM_010107584.1     GABRA5     garma-aminobutyric acid (GABA) receptor, alpha5  | _                |          |   |                   |             |
| XML_001790249.1     CKAP5     similar to colonic and hepatic tumor over-expressed protein     2.20*     0.81       NML_00110980.1     COL17A1     colagen, type XVII, alpha 1     0.76     2.05*       NML_001040036.1     DIN     dendrin     2.35*     0.97       NML_001040036.1     DINTIL     DIN11 dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NML_001040036.1     DINTIL     DIN11 dimethyladenosine transferase 1-like (S. cerevisiae)     3.82**     1.11       NML_001040052.1     DYNC1LII     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NML_001040055.1     EIN2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NML_00102151.1     ENDDD1     endonuclease domain containing 1     1.06     2.01*       NML_0010364.1     ELP2     elongation factor XI     1.01     2.01*       NML_0010384.1     GBRA2     gamma-aminoburyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NML_0010384.1.1     GABRA2     gamma-aminoburyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NML_0010384.1.1     GABRA2  | XM_583707.4      |          | •   | 2.55*             |             |
| NML_001101980.1     COL17A1     collagen, type XVII, alpha 1     0.76     2.06*       NML_00103434.01     CYR61     cystelme-rich, anglogenic inducer, 61     0.87     2.62***       NML_00103434.01     DIM     dendrin     2.35*     0.97       NML_001046036.1     DIMTIL     DIMI dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NML_001046036.1     DIVC1LI1     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NML_00104605.1     DIVC1LI1     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NML_0010364.1     ELP2     elongatom pretin 2 homolog (S. cerevisiae)     2.53     2.32*       NML_00102519.1     ENDOD1     endouclease domain containing 1     1.45     2.49*       NML_00102584.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NML_0010384.11     GCM3     glutamate-systemie flags, molfifer subunit     1.22     2.50**       NML_0010384.11     GCM3     glutamatione Stransferase 3, mucin type     7.66**     2.47       NML_00103851.1     GCM3     glutamatione Str  | NM_176788.1      |          | CCAAT/enhancer binding protein (C/EBP), beta              |                   | 2.09*       |
| NM_001034340.1     CYR61     cysteine-rkh, anglogenic inducer, 61     0.87     2.62**       NM_0010230.1     DDN     dendrin     2.35     0.97       NM_001010320.1     DIN1     dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.33       NM_001046052.1     DYNC1LI     divinein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NM_00114585.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     3.82***     1.11       NM_0010105021.1     END2D     elondator XI and the cerevisiae     3.82***     1.11       NM_001005651.1     F11     coagulation factor XI     1.01     2.01*       NM_174541.2     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34*       NM_00103844.1     GABRAS     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_0010384.1     GAIM     glucosaminyl (N-acety)I transferase 3. mucin type     7.66**     2.74       NM_0010381.31     GER     giuratae-cystein digae, modifier subanit     1.22     2.05**       NM_0010381.31     GER     similar to gastric intrinsic factor (vit  | XM_001790249.1   | CKAP5    |   | 2.20*             | 0.81        |
| NM_001102301.1     DDN     dendrin     2.35*     0.97       NM_0011002301.1     DDN     dendrin     2.35*     0.97       NM_001046036.1     DIMTIL     DMI dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NM_001046052.1     DYNCLILI     deiodinase, iodothyronine, type     4.38*     2.41*       NM_001143864.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_00100551.1     FL1     coagulation factor XI     1.01     2.01*       NM_0101008665.1     F11     coagulation factor XI     1.01     2.01*       NM_010103814.1     GRBRAS     gamma-aminobutyric acid (GA8A) A receptor, alpha 2     1.57     2.34**       NM_00103814.1     GRLM     glucasaminyl (M-acetyl) transferase 3, mucin type     7.66**     2.47       NM_26526.53     GPR120     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       NM_00108354.1     GSTM4     glutathione 5-transferase mu 4     2.81*     1.61       NM_00108354.1     GSTM4     glutathione 5-transferase mu 4     2.02*     0.43   | NM_001101980.1   | COL17A1  | collagen, type XVII, alpha 1                              | 0.76              | 2.06*       |
| NM_001046036.1     DIMT1L     DIM1 dimethyladenosine transferase 1-like (S. cerevisiae)     2.77*     1.23       NM_0010109923     DIO2     deiodinase, iodothyronine, type     4.38*     2.41*       NM_001146052.1     DYNC1LII     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NM_00114364.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_00105519.1     ENDOD1     endonuclease domain containing 1     1.45     2.49*       NM_00108665.1     F11     coagulation factor XI     1.01     2.01*       NM_001057844.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34**       NM_00103814.3.1     GCLM     glucasaming/(N-acery)t Inarferase 3, mucin type     7.66**     2.47       XM_26526.3     GPR120     similar to G protein-coupled receptor 120     2.02*     1.25       NM_001080351.1     HGF     similar to Act domain and RLD 6     0.74     2.65*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_001035151.1     HLA-A     major histocompatibibilty complex, clas  | NM_001034340.1   | CYR61    | cysteine-rich, angiogenic inducer, 61                     | 0.87              | 2.62**      |
| NM_00101992.3     DIO2     deiodinase, iodothyronine, type     4.38*     2.41*       NM_001046052.1     DYNC1LII     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NM_00112519.1     ENDOD1     enongation protein 2 homolog (S. cerevisiae)     38.2**     1.11       NM_001008665.1     F11     coagulation factor XI     1.01     2.01*       NM_00108665.1     F11     coagulation factor XI     1.01     2.01*       NM_00108865.1     F11     coagulation factor XI     1.01     2.01*       NM_001088143.1     GCLM     glutamate-cysteine ligase, modifier subunit     1.22     2.50**       NM_001088143.1     GCLM     glucosaminyl (N-acety) transferase 3, mucin type     7.6**     2.47       NM_001080354.1     GSTM4     glucosaminyl (N-acety) transferase mu 4     2.81*     1.61       MM_001080354.1     HERG6     similar to G protein-coupled receptor 120     2.02*     1.25       NM_001080351.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       NM_001010551.1     HLA-A     major histocompatibility complex, class I, A     2.0   | NM_001102301.1   | DDN      | dendrin   | 2.35*             | 0.97        |
| NM_001046052.1     DYNC1L1I     dynein, cytoplasmic 1, light intermediate chain 1     2.09*     0.74       NM_001143864.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     3.82**     1.11       NM_001102519.1     ENDOD1     endonuclease domain containing 1     1.45     2.49*       NM_001006665.1     F11     coagulation factor XI     1.01     2.01*       NM_01075844.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34*       NM_001075844.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_001037584.1     GLM     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       NM_00103854.1     GFK     ginalar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       NM_00103751.1     HGF     epatocyte growth factor     2.01*     1.43       NM_00103751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_00103751.1     HGF     hepatocyte growth factor     2.07*     1.43       NM_00103651.1     HTATP     Hix1 Ta interactive protein 2.3 0 kDa  | NM_001046036.1   |          | DIM1 dimethyladenosine transferase 1-like (S. cerevisiae) | 2.77*             | 1.23        |
| NNL_001143864.1     ELP2     elongation protein 2 homolog (S. cerevisiae)     382**     1.11       NML_001102519.1     ENDOD1     endonuclease domain containing 1     1.45     2.49*       XML_61483.4     ETV5     similar to ets variant gene 5 (ets-related molecule)     2.53     2.32*       NML_001008665.1     F11     coagulation factor XI     1.01     2.01*       NML_001075844.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34**       NML_001038143.1     GCLM     glutamate-cystelne ligase, modifier subunit     1.22     2.50**       NML_001080354.1     GSTM4     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       NML_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       XML_605913.4     HERC6     similar to G protein-coupled receptor 120     2.02*     1.43       NML_001017551.1     HLA-A     major histocompatibility complex, class I, A     2.02     0.43       NML_00102531.1     HLA-A     major histocompatibility complex, class I, A     2.00*     1.11       NML_001010551.1     HLA-A     major hi  | NM_001010992.3   | DIO2     | deiodinase, iodothyronine, type                           | 4.38*             | 2.41*       |
| NM_001102519.1     ENDOD1     endonuclease domain containing 1     1.45     2.49*       XM_014833.4     ETV5     similar to ets variant gene 5 (ets-related molecule)     2.53     2.32*       NM_001008665.1     F11     coagulation factor XI     1.01     2.01*       NM_001075844.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34*       NM_001075844.1     GABRA5     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_001081813.1     GCLM     glutamate-cysteine ligase, modifier subunit     1.22     2.50**       NM_001080354.1     GSTM4     glutosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       NM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       NM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       NM_00107612.1     HERC6     similar to hext domain and RLD 6     0.74     2.62*       NM_00107612.1     HGF     hepatocyte growth factor     2.00     4.33       NM_00107612.1     HGF     intertecora sylicity complex, class 1, A <td< td=""><td>NM_001046052.1</td><td>DYNC1LI1</td><td>dynein, cytoplasmic 1, light intermediate chain 1</td><td>2.09*</td><td>0.74</td></td<>          | NM_001046052.1   | DYNC1LI1 | dynein, cytoplasmic 1, light intermediate chain 1         | 2.09*             | 0.74        |
| XM_614853.4     ETVS     similar to ets variant gene 5 (ets-related molecule)     2.53     2.22*       NM_001008665.1     F11     coagulation factor XI     1.01     2.01*       NM_00107584.1     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34**       NM_00107584.1     GCLM     glutamate-crysteine ligase, modifier subunit     2.2     2.0***       NM_0010814.1     GCLM     glutamate-crysteine ligase, modifier subunit     2.0     2.02**     1.2       NM_0010834.1     GCLM     glutamate crysteine ligase, modifier subunit     2.0     2.02*     1.25       NM_00108035.1     GFR     similar to garotein-coupled receptor 120     2.0*     1.61       NM_00108035.1     GFR     similar to fer torian-coupled receptor 120     2.0*     1.43       NM_00108035.1.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_00103175.1.1     HGF     hepatan sulfate (glucosamine) 3-0-sulfotransferase 1     1.22     2.00**       NM_0010656.1.1     HLA-A     major histocompatibility complex, class I, A     2.02     0.43       NM_001055.1.1     HGF   | NM_001143864.1   | ELP2     | elongation protein 2 homolog (S. cerevisiae)              | 3.82**            | 1.11        |
| NM_001008665.1     F11     coagulation factor XI     1.01     2.01*       NM_174541.2     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34**       NM_001075844.1     GABRA5     gamma-aminobutyric acid (GABA) A receptor, alpha 2     2.34     0.49**       NM_001075844.1     GABRA5     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_001038143.1     GCLM     glutcosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       XM_265266.3     GPR120     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69***       NM_001030531.4     HERC     similar to for todmain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05     1.43       NM_0010253142.1     KSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       NM_00107584.1     HLPA     major histocompatibility complex, class I, A     2.02*     1.35       NM_00107612.1     HS3T     heparox sufface (glucosamine) 3-0-suffortansferase 1     1.22     2.00**       NM_00107584.1     HTAT     in  | NM_001102519.1   | ENDOD1   | endonuclease domain containing 1                          | 1.45              | 2.49*       |
| NM_174541.2     GABRA2     gamma-aminobutyric acid (GABA) A receptor, alpha 2     1.57     2.34**       NM_001075844.1     GABRA5     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_001075844.1     GABRA5     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_00107584.1     GCLM     glutamate-cysteine ligase, modifier subunit     1.22     2.50*       NM_00107584.3     GCNT3     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       NM_001080354.1     GSTM4     glutathione 5-transferase mu 4     2.81*     1.61       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_00107612.1     HGA-     major histocompatibility complex, class I, A     2.02*     0.50*       NM_00107612.1     HGA-     major histocompatibility complex, class I, A     2.07*     1.15       NM_00107558.1     HCA-     major histocompatibility complex, class I, A     2.07*     1.15       NM_00107612.1     HGA-     major histocompatibility complex, class I, A     2.07*     1.15       NM_00107558.1     IF/6 <td< td=""><td>KM_614853.4</td><td>ETV5</td><td>similar to ets variant gene 5 (ets-related molecule)</td><td>2.53</td><td>2.32*</td></td<> | KM_614853.4      | ETV5     | similar to ets variant gene 5 (ets-related molecule)      | 2.53              | 2.32*       |
| MM_001075844.1     GABRAS     gamma-aminobutyric acid (GABA) A receptor, alpha 5     2.34     0.49**       NM_001038143.1     GCLM     glutamate-cysteine ligase, modifier subunit     1.22     2.50**       VM_205809.1     GCNT3     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       KM_268229.3     GIF     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       KM_2608354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       KM_2605913.4     HERC6     similar to hext domain and RLD 6     0.74     2.62*       VM_001031751.1     HGF     hepatocyte growth factor     2.00*     0.43       VM_0010253142.1     KSR2     similar to Kinase suppressor of Ra 2     2.10     0.50*       VM_001040561.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       VM_001010561.1     HLA-A     major histocompatibility complex, class I, A     2.00*     1.15       VM_001040541.1     HTATIP2     HV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       VM_00104542.1     ILT3A     interferon, alpha-induc  | NM_001008665.1   | F11      | coagulation factor XI                                     | 1.01              | 2.01*       |
| NM_001038143.1     GCLM     glutamate-cysteine ligase, modifier subunit     1.22     2.50**       NM_205809.1     GCNT3     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       KM_2652663     GFR     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       NM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_0010125314.2.1     KSR2     similar to hect domain and RLD 6     0.74     2.62*       NM_0010125314.2.1     KSR2     similar to kinase suppressor of Ras 2     2.10     0.50*       NM_001076122.1     HS3T1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_00107558.1     IHTATIP< HIV-1 Tat interactive protein 2, 30 kDa   | NM_174541.2      | GABRA2   | gamma-aminobutyric acid (GABA) A receptor, alpha 2        | 1.57              | 2.34**      |
| NM_205809.1     GCNT3     glucosaminyl (N-acetyl) transferase 3, mucin type     7.66**     2.47       KM_865229.3     GIF     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       KM_865266.3     GPR120     similar to G protein-coupled receptor 120     2.02*     1.25       VM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       KM_605913.4     HERC6     similar to hect domain and RLD 6     0.74     2.62*       VM_0010551.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       KM_00107512.1     HSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       VM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       VM_00107588.1     IFI6     interferon, alpha-inducible protein 6     0.17     2.55*       VM_001046210.1     ILTR*     keratin 7     2.30*     1.87       KM_59057.4     KIAA0415     hypothetical protein LOS15222     1.30     2.45*       VM_001046210.1     ILTR*     similar to Lipase member M precursor     1.57     <  | NM_001075844.1   | GABRA5   | gamma-aminobutyric acid (GABA) A receptor, alpha 5        | 2.34              | 0.49**      |
| XM_868229.3     GIF     similar to gastric intrinsic factor (vitamin B synthesis)     0.80     3.69**       XM_865266.3     GPR120     similar to G protein-coupled receptor 120     2.02*     1.25       NM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       XM_605913.4     HERC6     similar to hext domain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_001031651.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       NM_001076122.1     HSST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_0101040563.1     HTATIP2     HIV-1 Tat interactive protein 6     0.17     2.55*       NM_001046210.1     ILR2     interleukin 1 receptor, type II     1.03     2.06*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*<  | NM_001038143.1   | GCLM     | glutamate-cysteine ligase, modifier subunit               | 1.22              | 2.50**      |
| KM_865266.3     GPR120     similar to G protein-coupled receptor 120     2.02*     1.25       NM_001080354.1     GSTM4     glutathione S-transferase mu 4     2.81*     1.61       KM_605913.4     HERC6     similar to hect domain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_00105651.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       NM_001076122.1     HSST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001040563.1     HTRTIP2     HiV-1 Tat interactive protein 6     0.17     2.55*       NM_001046210.1     IL1R2     interferon, alpha-inducible protein 6     0.17     2.55*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       KM_595458.4     LIPM     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97 <td>VM_205809.1</td> <td>GCNT3</td> <td>glucosaminyl (N-acetyl) transferase 3, mucin type</td> <td>7.66**</td> <td>2.47</td>                            | VM_205809.1      | GCNT3    | glucosaminyl (N-acetyl) transferase 3, mucin type         | 7.66**            | 2.47        |
| Number     GSTM4     glutathione Stransferase mu 4     2.81*     1.61       XM_6005913.4     HERC6     similar to hect domain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_001105651.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       XM_001253142.1     KSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       NM_001076122.1     HSST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 6     0.17     2.55*       NM_001046210.1     IL1R2     interleukin 1 receptor, type II     1.03     2.06*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*   | XM_868229.3      | GIF      | similar to gastric intrinsic factor (vitamin B synthesis) | 0.80              | 3.69**      |
| XXM_605913.4     HERC6     similar to hect domain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_001105651.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       XM_001253142.1     KSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       NM_001076122.1     HSST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001040563.1     HIC     interferon, alpha-inducible protein 6     0.17     2.55*       NM_00104621.01     IL1R2     interleukin 1 receptor, type II     1.03     2.06*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**  | XM_865266.3      | GPR120   | similar to G protein-coupled receptor 120                 | 2.02*             | 1.25        |
| XXM_605913.4     HERC6     similar to hect domain and RLD 6     0.74     2.62*       NM_001031751.1     HGF     hepatocyte growth factor     2.05*     1.43       NM_001105651.1     HLA-A     major histocompatibility complex, class I, A     2.02*     0.43       XM_001253142.1     KSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       NM_001076122.1     HSST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001040563.1     HIC     interferon, alpha-inducible protein 6     0.17     2.55*       NM_00104621.01     IL1R2     interleukin 1 receptor, type II     1.03     2.06*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**  | NM_001080354.1   | GSTM4    | glutathione S-transferase mu 4                            | 2.81*             | 1.61        |
| NNL_001105651.1HLA-Amajor histocompatibility complex, class I, A2.02*0.43XML_001253142.1KSR2similar to Kinase suppressor of Ras 22.100.50*NML_001076122.1HS3ST1heparan sulfate (glucosamine) 3-O-sulfotransferase 11.222.00**NML_001040563.1HTATIP2HIV-1 Tat interactive protein 2, 30 kDa2.07*1.15NML_174644.2IDH3Aisocitrate dehydrogenase 3 (NAD+) alpha2.27*1.24NM_001040563.1IFI6interferon, alpha-inducible protein 60.172.55*NM_001046210.1IL1R2interleukin 1 receptor, type II1.032.06*XM_590057.4KIAA0415hypothetical protein LOC5125221.302.45*NM_001046411.1KRT7keratin 72.30*1.87XM_595458.4LIPMsimilar to Lipase member M precursor1.572.21*XM_001249810.2LONRF3similar to LON peptidase N-terminal domain and RING finger protein 30.972.06*NM_001097565.1LRP8low density lipoprotein receptor-related protein 82.57*1.79XM_001789987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*XM_613028.3NEBnebulin1.82**2.25*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**XM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19   | XM_605913.4      | HERC6    |   | 0.74              | 2.62*       |
| NNL_001105651.1HLA-Amajor histocompatibility complex, class I, A2.02*0.43XML_001253142.1KSR2similar to Kinase suppressor of Ras 22.100.50*NML_001076122.1HS3ST1heparan sulfate (glucosamine) 3-O-sulfotransferase 11.222.00**NML_001040563.1HTATIP2HIV-1 Tat interactive protein 2, 30 kDa2.07*1.15NML_174644.2IDH3Aisocitrate dehydrogenase 3 (NAD+) alpha2.27*1.24NM_001040563.1IFI6interferon, alpha-inducible protein 60.172.55*NM_001046210.1IL1R2interleukin 1 receptor, type II1.032.06*XM_590057.4KIAA0415hypothetical protein LOC5125221.302.45*NM_001046411.1KRT7keratin 72.30*1.87XM_595458.4LIPMsimilar to Lipase member M precursor1.572.21*XM_001249810.2LONRF3similar to LON peptidase N-terminal domain and RING finger protein 30.972.06*NM_001097565.1LRP8low density lipoprotein receptor-related protein 82.57*1.79XM_001789987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*XM_613028.3NEBnebulin1.82**2.25*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**XM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19   | NM 001031751.1   | HGF      | hepatocyte growth factor                                  | 2.05*             | 1.43        |
| KM_001253142.1     KSR2     similar to Kinase suppressor of Ras 2     2.10     0.50*       NM_001076122.1     HS3ST1     heparan sulfate (glucosamine) 3-O-sulfotransferase 1     1.22     2.00**       NM_00104563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_0104563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.24       NM_01075588.1     IFI6     interferon, alpha-inducible protein 6     0.17     2.55*       NM_001046210.1     IL1R2     interleukin 1 receptor, type II     1.03     2.06*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       XM_0010249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_010197565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       XM_0173940.2     MX1     mycovirus (influenza virus) resistance 1     0.54     2.05*       NM_173940.2     MX1     mycovirus (influenza virus) resistan  |                  |          |   |                   |             |
| NumberHS3ST1heparan sulfate (glucosamine) 3-O-sulfotransferase 11.222.00**NM_001040563.1HTATIP2HIV-1 Tat interactive protein 2, 30 kDa2.07*1.15NM_174644.2IDH3Aisocitrate dehydrogenase 3 (NAD+) alpha2.27*1.24NM_001075588.1IFI6interferon, alpha-inducible protein 60.172.55*NM_001046210.1IL1R2interleukin 1 receptor, type II1.032.06*NM_001046411.1KRT7keratin 72.30*1.87XM_001046411.1KRT7keratin 72.21*2.21*XM_0010249810.2LONRF3similar to Lipase member M precursor1.572.21*NM_001097565.1LPPlactoperoxidase2.330.16**NM_0010789987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**XM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19  | XM 001253142.1   | KSR2     |   | 2.10              | 0.50*       |
| ML_001040563.1     HTATIP2     HIV-1 Tat interactive protein 2, 30 kDa     2.07*     1.15       NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001075588.1     IFI6     interferon, alpha-inducible protein 6     0.17     2.55*       NM_001046210.1     IL1R2     interferon, alpha-inducible protein 6     0.13     2.06*       KM_590057.4     KIAA0415     hypothetical protein LOC512522     1.30     2.45*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       KM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       KM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**       NM_001097565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       KM_0173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2  |                  |          |   |                   |             |
| NM_174644.2     IDH3A     isocitrate dehydrogenase 3 (NAD+) alpha     2.27*     1.24       NM_001075588.1     IFI6     interferon, alpha-inducible protein 6     0.17     2.55*       NM_001046210.1     IL1R2     interleukin 1 receptor, type II     1.03     2.06*       XM_590057.4     KIAA0415     hypothetical protein LOC512522     1.30     2.45*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       XM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       XM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**       NM_001789987.1     KRT     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       NM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       NM_601076799.1 <td< td=""><td>_</td><td>HTATIP2</td><td></td><td>2.07*</td><td></td></td<>   | _                | HTATIP2  |   | 2.07*             |             |
| NM_001075588.1IFI6interferon, alpha-inducible protein 60.172.55*NM_001046210.1IL1R2interleukin 1 receptor, type II1.032.06*(M_590057.4KIAA0415hypothetical protein LOC5125221.302.45*NM_001046411.1KRT7keratin 72.30*1.87(M_595458.4LIPMsimilar to Lipase member M precursor1.572.21*(M_001249810.2LONRF3similar to LON peptidase N-terminal domain and RING finger protein 30.972.06*NM_173933.2LPOlactoperoxidase2.330.16**NM_001097565.1LRP8low density lipoprotein receptor-related protein 82.57*1.79KM_001739987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**KM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19  | _                |          | •   |                   |             |
| NM_001046210.1IL1R2interleukin 1 receptor, type II1.032.06*KM_590057.4KIAA0415hypothetical protein LOC5125221.302.45*NM_001046411.1KRT7keratin 72.30*1.87KM_595458.4LIPMsimilar to Lipase member M precursor1.572.21*KM_001249810.2LONRF3similar to LON peptidase N-terminal domain and RING finger protein 30.972.06*NM_173933.2LPOlactoperoxidase2.330.16**NM_001097565.1LRP8low density lipoprotein receptor-related protein 82.57*1.79KM_001789987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*KM_613028.3NEBnebulin1.82**2.25*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**KM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19  | —                |          |   |                   |             |
| KM_590057.4     KIAA0415     hypothetical protein LOC512522     1.30     2.45*       NM_001046411.1     KRT7     keratin 7     2.30*     1.87       KM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       KM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**       NM_001097565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       NM_001076799.1     NC82     nitric oxide synthase 2, inducible     0.97     2.18**       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       KM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19   | —                |          |   |                   |             |
| NM_001046411.1     KRT7     keratin 7     2.30*     1.87       KM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       KM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_17393.2     LPO     lactoperoxidase     2.33     0.16**       NM_001097565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       NM_001076799.1     NCS2     nitric oxide synthase 2, inducible     0.97     2.18**       NM_001076799.1     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19   | —                |          |   |                   |             |
| KM_595458.4     LIPM     similar to Lipase member M precursor     1.57     2.21*       KM_001249810.2     LONRF3     similar to LON peptidase N-terminal domain and RING finger protein 3     0.97     2.06*       NM_173933.2     LPO     lactoperoxidase     2.33     0.16**       NM_001097565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       NM_601076799.1     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       KM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.99  | —                |          |   |                   |             |
| KM_001249810.2LONRF3similar to LON peptidase N-terminal domain and RING finger protein 30.972.06*NM_173933.2LPOlactoperoxidase2.330.16**NM_001097565.1LRP8low density lipoprotein receptor-related protein 82.57*1.79KM_001789987.1METTL8methyltransferase like 80.872.20*NM_173940.2MX1myxovirus (influenza virus) resistance 10.542.05*KM_613028.3NEBnebulin1.82**2.25*NM_001076799.1NOS2nitric oxide synthase 2, inducible0.972.18**KM_592814.2P2RX1similar to P2X purinoceptor 1 (ATP receptor)3.14*1.19   |                  |          |   |                   |             |
| NM_173933.2     LPO     lactoperoxidase     2.33     0.16**       NM_001097565.1     LRP8     low density lipoprotein receptor-related protein 8     2.57*     1.79       KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       KM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       KM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | —                |          |   |                   |             |
| NM_001097565.1     LRP8     Iow density lipoprotein receptor-related protein 8     2.57*     1.79       KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       KM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       KM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | -                |          |   |                   |             |
| KM_001789987.1     METTL8     methyltransferase like 8     0.87     2.20*       NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       KM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       KM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | _                |          | •   |                   |             |
| NM_173940.2     MX1     myxovirus (influenza virus) resistance 1     0.54     2.05*       XM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       XM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | —                |          |   |                   |             |
| XM_613028.3     NEB     nebulin     1.82**     2.25*       NM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       XM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | —                |          |   |                   |             |
| MM_001076799.1     NOS2     nitric oxide synthase 2, inducible     0.97     2.18**       XM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19   | _                |          |   |                   |             |
| XM_592814.2     P2RX1     similar to P2X purinoceptor 1 (ATP receptor)     3.14*     1.19  | —                |          |   |                   |             |
|  | —                |          |   |                   |             |
| INIVI_UUTUUTUUTUUTUUTUUTUUTUUTUUTUUTUUTUUTUUT  |                  |          |   |                   |             |
|  | NIVI_001001600.1 | PGA5     | pepsinogen 5, group I (pepsinogen A)                      | 1.21              | 2.20*       |

#### Table 1 Genes significantly induced in the bovine small intestine by Cooperia oncophora infections\*


| (M_583514.4    | PGM2     | phosphoglucomutase 2   | 2.89*  | 0.70   |
|----------------|----------|--|--------|--------|
| IM_001035017.1 | PHGDH    | phosphoglycerate dehydrogenase   | 2.62*  | 1.09   |
| M_601308.3     | POLS     | similar to DNA polymerase sigma  | 1.01   | 2.06** |
| IM_174432.2    | PRDX3    | peroxiredoxin 3 (PRDX3)  | 2.16*  | 0.51   |
| IM_174690.1    | PRSS2    | protease, serine, 2 (trypsin 2)  | 3.44*  | 1.13   |
| IM_001105323.1 | PTGS1    | prostaglandin-endoperoxide synthase 1                                  | 2.39*  | 1.52   |
| IM_001103316.1 | PTPLAD1  | protein tyrosine phosphatase-like A domain containing 1                | 1.45   | 2.40*  |
| IM_001046303.1 | RELL2    | RELT-like 2  | 2.07   | 0.27** |
| IM_001080232.1 | RGS13    | regulator of G-protein signaling 13                                    | 1.26   | 2.63*  |
| IM_001045941.1 | RSAD2    | radical S-adenosyl methionine domain containing 2                      | 0.40   | 3.18*  |
| IM_173959.4    | SCD      | stearoyl-CoA desaturase (delta-9-desaturase)                           | 2.21*  | 0.95   |
| M_590757.3     | SEMA3B   | Sema domain, short basic domain, secreted,3B                           | 0.77   | 2.03*  |
| IM_001099211.1 | SF3A2    | splicing factor 3a, subunit 2, 66 kDa                                  | 1.03   | 2.12*  |
| M_001099378.1  | SLC15A1  | solute carrier family 15 (oligopeptide transporter), member 1          | 2.19*  | 0.57   |
| M_867835.3     | SLC22A15 | similar to solute carrier family 22, member 15                         | 1.58   | 2.57*  |
| M_176640.2     | SLC35A2  | solute carrier family 35 (UDP-galactose transporter), member A2        | 2.07*  | 1.30   |
| M_001790621.1  | SLC38A1  | solute carrier family 38, member 1                                     | 2.50*  | 1.70*  |
| M_001101994.1  | SLC6A12  | solute carrier family 6, member 12                                     | 2.08   | 0.32*  |
| M_174187.2     | SPP1     | secreted phosphoprotein 1  | 1.01   | 4.69*  |
| M_001046456.1  | TICAM2   | toll-like receptor adaptor molecule 2                                  | 3.29*  | 1.04   |
| M_001035107.1  | TINAG    | tubulointerstitial nephritis antigen                                   | 1.69   | 3.41*  |
| M_001076856.1  | TMEM66   | transmembrane protein 66   | 2.99*  | 1.03   |
| M_600015.4     | TNFSF9   | similar to tumor necrosis factor (ligand) superfamily, member 9        | 2.61** | 1.02   |
| M_001038155.1  | TNS4     | tensin 4   | 2.84*  | 1.88   |
| IM_001012284.1 | UBA7     | ubiquitin-like modifier activating enzyme 7                            | 0.38   | 2.37*  |
| M_001103233.1  | ULBP3    | UL16 binding protein 3   | 2.23*  | 0.31   |
| M_001035075.1  | XAF1     | XIAP associated factor 1   | 0.55   | 2.20** |
| M_001102354.1  | XRCC2    | X-ray repair complementing defective repair in Chinese hamster cells 2 | 1.40   | 2.36** |
| M_585095.4     | ZBP1     | similar to Z-DNA binding protein 1                                     | 0.44   | 2.20** |
| M_874604.3     | ZNF71    | similar to zinc finger protein 71                                      | 2.98*  | 1.14   |

| Table 1 Genes significantly induced in the bovine small intestine | by Cooperia oncophora infections* (Continued) |
|---|---|
|---|---|

\*Only sequences with annotation are listed.

complex, class I, A (HLA-A), toll-like receptor adaptor molecule 2 (TICAM2), and UL16 binding protein 3 (ULBP3). On the other hand, at least 44 genes, such as calbindin 1 (CALB1), collagen, type XVII, alpha 1 (COL17A1), interferon, alpha-inducible protein 6 (IFI6), interleukin 1 receptor, type II (IL1R2), nitric oxide synthase 2, inducible (NOS2), and secreted phosphoprotein 1 (SPP1, osteopontin), were significantly induced only during reinfection. Several genes, such as cadherinlike molecule 26 (CDH26), nebulin (NEB), deiodinase, iodothyronine, type II (DIO2), and solute carrier family 38, member 1 (SLC38A1), were significantly up-regulated during both the primary infection and reinfection. Genes significantly repressed during infection, such as adrenergic, alpha-1B-, receptor (ADRA1B), cytochrome P450, family 4, subfamily A, polypeptide 11 (CYP4A11), and hypoxia inducible factor 3, alpha subunit (HIF3A), were listed in Additional file 1.


Twenty three pathways were significantly impacted (P <0.05) during infection (Additional file 2). Eight pathways in which their genes were down-regulated during primary infection included fatty acid metabolism, lysine degradation, fatty acid elongation in mitochondria, and LPS/IL-1 mediated inhibition of RXR function. During reinfection, three pathways whose genes were down-regulated, such as calcium signaling and fatty acid metabolism, were significantly impacted. Fatty acid metabolism was seemingly the only pathway suppressed during both primary infection and reinfection. Twelve pathways were significantly stimulated during infections as evidenced by up-regulation of the genes involved in these pathways. LXR/RXR activation was the only pathway stimulated during both primary infection and reinfection while the VDR/RXR activation pathway was stimulated only during reinfection (Figure 1). Notably, NOS2 was involved in 5 out the 8 pathways impacted during reinfection. The eicosanoid pathway,



which is significantly impacted only at 28 dpi during *C. oncophora* primary infection in cattle [7], was not seemingly involved in the development of acquired resistance.


#### Quantitative PCR and Western blot analysis

The mRNA expression of 16 genes was analyzed using real-time RT-PCR (Additional file 3), which were selected on the basis of their presumed biological relevance. These include 10 genes in the eicosanoid pathway such as 5-lipoxygenase activating protein (ALOX5AP or FLAP), prostaglandin synthase 2 (PTGS2 or COX2), leukotriene A4 hydrolase (LTA4H), leukotriene C4 synthase (LTC4), and thromboxane A synthase (TBXAS1). While arachidonate 15-lipoxygenase (ALOX15) was slightly upregulated during reinfection, consistent with the results obtained using the oligo microarray, other genes, including COX2 (Figure 2), remained largely unchanged. Quantitative PCR also confirmed up-regulation of NOS2 at the mRNA level during reinfection (Figure 2). This gene was significantly up-regulated at 14 dpi based on quantitative PCR analysis, which is in agreement with the microarray results. CDH26 expression was induced to a much greater extent during primary infection than during reinfection, 82 vs. 21 fold (Figure 3), compared to their respective controls. The vitamin D3 receptor (VDR) expression was slightly elevated during both primary infection and reinfection ( $\approx 1.7$  fold) compared to its respective controls. The mRNA level of mucin 5B (MUC5b) in the small intestine was very low and unchanged during infection. However, MUC2 expression was up-regulated during primary infection but not during reinfection. Interestingly, GCNT3 mRNA followed the same pattern as MUC2, which were strongly upregulated only during primary infection, compared to




naïve controls. The relative amount of both MUC and GCNT3 mRNA molecules in the reinfected animals was indistinguishable from the drug-treated controls as well as from naïve controls (Figure 4).


Protein expression in the small intestine during infection was monitored using Western blot analysis (Figure 5). SPP1, a gene in the VDR/RXR activation pathway, was two fold higher in the reinfected animals (N = 4)



value of the naïve control group was set as 1.0. The fold change (N = 4) were calculated using the 2<sup>- $\Delta$ ACT</sup> method and normalized against the naïve control group (mean ± SD). CDH26 = cadherin 26.



compared to the drug-treated control (N = 4). This is consistent with mRNA results. SPP1 was also up-regulated in the primed animals (1.8 fold) compared to naïve controls. GCNT3 protein expression was elevated 3.5 fold during primary infection; and its elevated expression was maintained during reinfection but to a lesser extent (2.4 fold) compared to drug-treated controls (Figure 5).



#### Discussion

It has long been recognized that genetics plays an important role in the host's ability to resist gastrointestinal nematode infections in ruminants, even though the heritability of the resistance trait is relatively low to moderate in most cases. Different breeds and selection lines in ruminants differ greatly in their relative resistance [24-27]. Resistance is manifested in several distinct forms, including a reduced establishment of worms and retarded or arrested worm development as well as stunting and inhibition of egg production [28]. There have been numerous attempts to exploit the relative contribution of inherited components in susceptibility to GI nematodes in ruminants for its utilities in either applied breeding programs [29] or in understanding molecular mechanisms underlying the trait [17,27]. Acquired resistance, the ability of animals to become resistant after prior infection by pathogens, exposure to stress, or application of chemical inducers, is also well documented. In cattle, calves with previous exposure to a heavily contaminated pasture have a limited establishment of worms, compared to naïve calves that are exposed to the same pasture harboring over 380 times more worms [30]; the ability of calves to acquire resistance to C. oncophora appears to be independent of age. Several other studies also support the observation that priming with C. oncophora induces strong protective immunity, possibly due to its rapid elicitation of immunological reactions [16]. Understanding genetic and immunological mechanisms underlying the development of acquired resistance could have implications in vaccine design. While temporal responses of cytokine and biochemical pathways to C. oncophora infections, both natural and experimental, have been monitored recently [7,31,32], molecular mechanisms underlying the development of acquired resistance have yet to be unraveled.

In this study, twenty three pathways were significantly impacted in the bovine small intestine during C. oncophora infection. Among these pathways, the VDR/ RXR activation pathway was strongly impacted only during reinfection, suggesting that this pathway may have played an important role in the development of acquired resistance. VDR partners with the retinoid × receptor, RXR, a member of the nuclear hormone receptor family, to form a heterodimer VDR-RXR. The heterodimer is then bound to Vitamin D3 as well as other co-activator proteins to mediate the transcriptional regulation of a number of genes. The activation plays a crucial role in the regulation and metabolism of calcium and phosphorus in the small intestine, kidney and bone as well as modulates the expression of genes in bile acid transport [33]. However, the function of VDR extends far beyond its classical boundary as a regulator of calcium homeostasis and bone metabolism. VDR is constitutively expressed in a variety of immune cells and plays an essential role in gastrointestinal inflammation and innate and adaptive immunity [34]. Mounting evidence suggests any disruption to vitamin D and/or its receptor could have serious consequences in a number of the key physiological processes, including immune function. VDR knock-out (KO) mice exhibit a pro-inflammatory bias and abolish the formation of NF- $\kappa$ B-VDR complex. VDR KO mice have reduced CD4/ CD8 $\alpha$   $\alpha$  intraepithelial lymphocyte populations in the gut and compromised T cell homing [35]. Therefore, VDR is an important contributor to host protection from bacterial infection and associated with colon tumor progress [36]. Vitamin D3 (calcitriol) treatment in humans induces a significant increase in circulating lymphocytes and the percentage of eosinophil vacuolization [37], a condition favoring a Th2 immune response, a hallmark of parasitic nematode infection. Our results show that increased expression of VDR and strong stimulation of the VDR/ RXR activation pathway during C. oncophora reinfection may contribute to intestinal repair. Many previously published reports demonstrate that vitamin D3 induces an increased expression of tight junction proteins such as claudins as well as E-cadherin; and its receptor, VDR, and is able to enhance the intercellular junctions [38]. VDR knockdown compromises tight junction functions. VDR plays important roles in maintaining the integrity of the intestinal mucosal barrier. While further evidence is needed to establish a solid link between the VDR pathway and the development of acquired resistance to C. oncophora infection in cattle, our findings nevertheless provide a novel direction for future research.

Nitric oxide (NO), one of the most versatile players in the immune system, is critical in host defense because of its cytotoxic and immunoregulatory properties [39,40]. The production of NO by nitric oxide synthases (NOS) in various cell types including macrophages is mainly controlled at the transcriptional level. Inducible nitric oxide synthase (NOS2) is widely expressed in many cell types. NOS2 is readily inducible by cytokines such as TNF $\alpha$ , IL-1 $\beta$ , and IFN- and/or microbial products, resulting in sufficient and sustained production of NO. NO in turn exerts numerous effector and immunoregulatory functions including killing of infectious pathogens and modulating cytokine production and Th cell development [41]. Reactive nitrogen intermediates (NO and its derivatives) are among the key effector molecules of parasite control in the livers of L. donovani-infected mice [42]. The host capable of controlling the infection of this intracellular parasite develops an effective T cell- dependent immune response mediated largely by Th1 cytokines, including IL-12 and IFN- $\gamma$ . On the other hand, Th2 cells play a central role in mediating the protective immunity against parasitic nematode infections by releasing an array of cytokines,

such as IL-4 and IL-13. These cytokines, via their receptors such as IL-4 receptor  $\alpha$  (IL-4R $\alpha$ ), activates downstream signaling pathways. However, the induction of a Th2-type immune response leading to worm expulsion is complicated. A recent study suggests that neither the expression of this receptor on CD4<sup>+</sup> T cells nor macrophages and neutrophils are required for protective immunity to *Trichinella spiralis* infection in mice [43].

Cooperia oncophora infection in cattle induces a Th2 immune response. However, dominant effector mechanisms controlling worm expulsion have yet to be identified. A significant increase in mucous IgA and IgG1 as well as an influx of eosinophils are evident during primary infection [7,9]. Th2 cytokines such as IL-4 and IL-13 are strongly up-regulated during a primary infection while TNF $\alpha$  and IFN- $\gamma$  remains largely unchanged. Results from this study demonstrated that NOS2 expression was up-regulated during reinfection (Figure 2). NOS2 was implicated in 5 of the 8 pathways induced during reinfection, including IL-12 signaling, IL-17 signaling, IL-6 signaling, and glucocorticoid receptor signaling pathways. The expression of IL-12 during *C. oncophora* infection in the bovine small intestine was not monitored in this study. Published studies suggest that ongoing Th2 responses are relatively stable and difficult to switch to a Th1 response [44]. IL-12 is a potent stimulus for Th1 responses and has previously shown to drive chronic T. muris infection in a normally resistant mouse strain [45,46]. Resistance can be generated either by a single infection event which exceeds the threshold or multiple sub-threshold infection episodes. The absolute level of parasites required to reach threshold varies between genetically distinct individuals. While resistance is generally associated with Th2 responses, it is possible that the development of acquired resistance to C. oncophora infection in cattle requires a delicate balance between the production of Th1 cytokines and Th2 cytokines.

The interaction of pathogen-associated molecular patterns such as carbohydrate moieties on parasites by host pattern recognition receptors (e.g. collectins and galectins) triggers a cascade of events, including activation of various immune cells and subsequent cytokine production and resultant recruitment of leukocytes to the site of infection in the bovine small intestine. A sustained elevation of inflammatory cytokines during priming induces NOS2 gene expression, leading to increased production of NO. These reactive nitrogen species and proteases released by infiltrates create a hostile environment for parasites, which impacts worm establishment and reproduction. Up-regulation of genes in extracellular matrix and tight junction as well as genes involved in mucin biosynthesis by infection may lead to enhanced tissue repair in the small intestine. These factors all

contribute to the rapid development of acquired resistance to *C. oncophora* infection in cattle after priming by a high-dose primary infection.

In conclusion, we presented evidence that acquired resistance to C. oncophora infection in cattle can be rapidly developed following priming of the immune response. Multiple signaling pathways that were significantly impacted during reinfection were identified, distinct from those during a primary infection. The VDR/ RXR activation pathway may have contributed significantly to the development of acquired resistance via its potential roles in immune regulation and intestinal mucosal integrity maintenance. NOS2 expression was strongly induced; and several NOS2 associated pathways were significantly impacted during reinfection, suggesting they may play an important role in protective immunity. However, the development of acquired resistance is likely to be very complicated. The relative contribution of Th1 and Th2 immune responses to the resolution of C. oncophora infection in cattle needs to be experimentally defined.

#### **Additional material**

Additional file 1: Genes significantly impacted during *Cooperia oncophora* infections in cattle. 308 unique sequences significantly regulated during *Cooperia oncophora* infections in cattle.

Additional file 2: Pathways significantly impacted during *Cooperia oncophora* infections in cattle. 23 canonical pathways significantly impacted during *Cooperia oncophora* infections in cattle.

Additional file 3: Primers used in the experiment. Primers for 15 genes used in the experiment.

#### Acknowledgements

The authors thank Debbie Hebert and Joanne Wilson for their excellent technical assistance. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the U. S. Department of Agriculture.

#### Authors' contributions

RWL conceived the study, conducted the experiment, analyzed the data, and drafted the manuscript. CJL carried out Western blot analysis. LCG assisted in parasite infection experiments. All authors read and approved the final manuscript.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Received: 5 October 2010 Accepted: 17 March 2011 Published: 17 March 2011

#### References

- Lima WS: Seasonal infection pattern of gastrointestinal nematodes of beef cattle in Minas Gerais State-Brazil. Vet Parasitol 1998, 74:203-214.
- Coop RL, Sykes AR, Angus KW: The pathogenicity of daily intakes of Cooperia oncophora larvae in growing calves. Vet Parasitol 1979, 5:261-269.
- Armour J, Bairden K, Holmes PH, Parkins JJ, Ploeger H, Salman SK, McWilliam PN: Pathophysiological and parasitological studies on Cooperia oncophora infections in calves. Res Vet Sci 1987, 42:373-381.

- Li RW, Li C, Elsasser TH, Liu G, Garrett WM, Gasbarre LC: Mucin biosynthesis in the bovine goblet cell induced by *Cooperia oncophora* infection. *Vet Parasitol* 2009, 165:281-289.
- 5. Gasbarre LC, Leighton EA, Sonstegard T: Role of the bovine immune system and genome in resistance to gastrointestinal nematodes. *Vet Parasitol* 2001, **98**:51-64.
- Kanobana K, Ploeger HW, Vervelde L: Immune expulsion of the trichostrongylid Cooperia oncophora is associated with increased eosinophilia and mucosal IgA. Int J Parasitol 2002, 32:1389-1398.
- Li RW, Gasbarre LC: A temporal shift in regulatory networks and pathways in the bovine small intestine during *Cooperia oncophora* infection. *Int J Parasitol* 2009, 39:813-824.
- Kanobana K, Koets A, Kooyman FN, Bakker N, Ploeger HW, Vervelde L: B cells and antibody response in calves primary-infected or re-infected with *Cooperia oncophora*: influence of priming dose and host responder types. Int J Parasitol 2003, 33:1487-1502.
- Kanobana K, Vervelde L, Van Der Veer M, Eysker M, Ploeger HW: Characterization of host responder types after a single *Cooperia* oncophora infection: kinetics of the systemic immune response. *Parasite Immunol* 2001, 23:641-653.
- Nieuwland MG, Ploeger HW, Kloosterman A, Parmentier HK: Systemic antibody responses of calves to low molecular weight *Cooperia* oncophora antigens. Vet Parasitol 1995, 59:231-239.
- Dobson RJ, Waller PJ, Donald AD: Population dynamics of *Trichostrongylus* colubriformis in sheep: the effect of host age on the establishment of infective larvae. Int J Parasitol 1990, 20:353-357.
- 12. Gasbarre LC, Leighton EA, Davies CJ: Influence of host genetics upon antibody responses against gastrointestinal nematode infections in cattle. *Vet Parasitol* 1993, **46**:81-91.
- Li RW, Hou Y, Li C, Gasbarre LC: Localized complement activation in the development of protective immunity against *Ostertagia ostertagi* infections in cattle. *Vet Parasitol* 2010, 175:247-256.
- Kanobana K, Ploeger HW, Eysker M, Vervelde L: Individual variation and effect of priming dose level on establishment, growth and fecundity of *Cooperia oncophora* in re-infected calves. *Parasitology* 2004, 128:99-109.
- Dorny P, Claerebout E, Vercruysse J, Hilderson H, Huntley JF: The influence of a *Cooperia oncophora* priming on a concurrent challenge with *Ostertagia ostertagi* and *C. oncophora* in calves. *Vet Parasitol* 1997, 70:143-151.
- Eysker M, Boersema JH, Kooyman FN, Ploeger HW: Resilience of second year grazing cattle to parasitic gastroenteritis following negligible to moderate exposure to gastrointestinal nematode infections in their first year. Vet Parasitol 2000, 89:37-50.
- Li RW, Meyer MJ, Van Tassell CP, Sonstegard TS, Connor EE, Van Amburgh ME, Boisclair YR, Capuco AV: Identification of estrogenresponsive genes in the parenchyma and fat pad of the bovine mammary gland by microarray analysis. *Physiol Genomics* 2006, 27:42-53.
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>△△CT</sup> Method. *Methods* 2001, 25:402-408.
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scheff U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics* 2003, 4:249-264.
- Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* 2003, 19:185-193.
- 21. MultiExperiment Viewer. [http://www.tm4.org/mev].
- Guo L, Lobenhofer EK, Wang C, Shippy R, Harris SC, Zhang L, Mei N, Chen T, Herman D, Goodsaid FM, Hurban P, Phillips KL, Xu J, Deng X, Sun YA, Tong W, Dragan YP, Shi L: Rat toxicogenomic study reveals analytical consistency across microarray platforms. *Nat Biotechnol* 2006, 24:1162-1169.
- Li RW, Capuco AV: Canonical pathways and networks regulated by estrogen in the bovine mammary gland. Funct Integr Genomics 2008, 8:55-68.
- 24. Burke JM, Miller JE: Relative resistance of Dorper crossbred ewes to gastrointestinal nematode infection compared with St. Croix and Katahdin ewes in the southeastern United States. *Vet Parasitol* 2009, 109:265-275.
- 25. Golding N, Small RW: The relative resistance to gastrointestinal nematode infection of three British sheep breeds. *Res Vet Sci* 2009, **87**:263-264.

- Gonzalez JF, Hernandez A, Molina JM, Fernandez A, Raadsma HW, Meeusen EN, Piedrafita D: Comparative experimental *Haemonchus* contortus infection of two sheep breeds native to the Canary Islands. *Vet Parasitol* 2008, 153:374-378.
- Li RW, Sonstegard TS, Van Tassell CP, Gasbarre LC: Local inflammation as a possible mechanism of resistance to gastrointestinal nematodes in Angus heifers. Vet Parasitol 2007, 145:100-107.
- Michel JF: Some aspects of resistance to animal and human helminths. Acquired resistance and its effect on populations of Ostertagia ostertagi. Proc R Soc Med 1967, 60:167-168.
- Coppieters W, Mes TH, Druet T, Farnir F, Tamma N, Schrooten C, Cornelissen AW, Georges M, Ploeger HW: Mapping QTL influencing gastrointestinal nematode burden in Dutch Holstein-Friesian dairy cattle. BMC Genomics 2009, 10:96.
- Smith HJ, Archibald RM: The effects of age and previous infection on the development of gastrointestinal parasitism in cattle. Can J Comp Med 1968, 32:511-517.
- Bricarello PA, Zaros LG, Coutinho LL, Rocha RA, Silva MB, Kooyman FN, de Vries E, Yatsuda AP, Amarantem AF: Immunological responses and cytokine gene expression analysis to *Cooperia punctata* infections in resistant and susceptible Nelore cattle. *Vet Parasitol* 2008, 155:95-103.
- Li RW, Gasbarre LC: Gene expression in the bovine gastrointestinal tract during nematode infection. In *Veterinary Parasitology*. Edited by: LaMann G. Nova Biomedical Press, New York; 2010:157-178.
- Ogura M, Nishida S, Ishizawa M, Sakurai K, Shimizu M, Matsuo S, Amano S, Uno S, Makishima M: Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. *J Pharmacol Exp Ther* 2009, 328:564-570.
- Froicu M, Zhu Y, Cantorna MT: Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. *Immunology* 2006, 117:310-318.
- Yu S, Bruce D, Froicu M, Weaver V, Cantorna MT: Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. *Proc Natl Acad Sci USA* 2008, 105:20834-20839.
- Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M, Sawada T, Nakata B, Ohira M, Hirakawa K: Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009, 22:1021-1025.
- Snyman JR, de Sommers K, Steinmann MA, Lizamore DJ: Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis. Eur J Clin Pharmacol 1997, 52:277-280.
- Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC: Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008, 294: G208-G216.
- 39. Garcia X, Stein F: Nitric oxide. Semin Pediatr Infect Dis 2006, 17:55-57.
- Murray HW, Nathan CF: Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 1999, 189:741-746.
- Nathan C, Shiloh MU: Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 2000, 97:8841-8848.
- 42. Bogdan C: Nitric oxide and the immune response. *Nat Immunol* 2001, 2:907-916.
- Michels CE, Scales HE, Saunders KA, McGowan S, Brombracher F, Alexander J, Lawrence CE: Neither interleukin-4 receptor alpha expression on CD4+ T cells, or macrophages and neutrophils is required for protective immunity to *Trichinella spiralis*. *Immunology* 2009, 128: e385-e394.
- 44. Perez VL, Lederer JA, Lichtman AH, Abbas AK: Stability of Th1 and Th2 populations. Int Immunol 1995, 7:869-875.
- Bancroft AJ, Else KJ, Humphreys NE, Grencis RK: The effect of challenge and trickle *Trichuris muris* infections on the polarisation of the immune response. Int J Parasitol 2001, 31:1627-1637.
- Bancroft AJ, Else KJ, Sypek JP, Grencis RK: Interleukin-12 promotes a chronic intestinal nematode infection. Eur J Immunol 1997, 27:866-870.

#### doi:10.1186/1297-9716-42-48

**Cite this article as:** Li *et al*: The vitamin D receptor and inducible nitric oxide synthase associated pathways in acquired resistance to *Cooperia oncophora* infection in cattle. *Veterinary Research* 2011 **42**:48.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit